BioSpace News Archive

Drug Development

Outclassed by Eliquis, Bayer Halts Atrial Fibrillation Study of Factor XIa Inhibitor

Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’ and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.

November 20, 2023
·
2 min read
·
Tristan Manalac
Drug Development

With New Phase III Data in Hand, Servier Eyes FDA Filing for Glioma Candidate

Vorasidenib decreased tumor volume by a mean of 2.5% every six months, compared to growth of 13.9% for placebo over the same time span. The candidate is also being tested in a regimen with Keytruda.

November 20, 2023
·
2 min read
·
Tristan Manalac
From the Bench to the Office: Advice for Graduate Students Considering Leaving Academia

A biopharma communications professional offers advice he wishes he’d received as a PhD student considering a career in industry.

November 20, 2023
·
11 min read
·
Ignacio Guerrero-Ros
Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market

The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.

November 20, 2023
·
4 min read
·
Patience Asanga
NHS, Pharma Deal Doubles Annual Growth and Earmarks £400M for R&D

The new five-year deal will save the U.K.’s National Health Service an estimated £14 billion ($17.4 billion) and double the annual allowed growth in sales of branded medicines from 2% to 4% per year by 2027.

November 20, 2023
·
2 min read
·
Connor Lynch
Deals

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.

November 20, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Next-Generation ADCs Strive to Overcome Toxicities, Payload Problems

As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?

November 20, 2023
·
5 min read
·
Hayley Shasteen
Bio NC

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Basilea Pharmaceutica Ltd announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc.

November 20, 2023
·
3 min read
Biotech Bay

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology Annual Meeting last week.

November 20, 2023
·
3 min read
Drug Development

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

Omnix Medical announced that the U.S. Food and Drug Administration has approved a planned Phase II trial of the Company´s novel anti-infective OMN6.

November 20, 2023
·
3 min read